Neurobehavioral actions of cannabichromene and interactions with Δ9-tetrahydrocannabinol

Davis, William S.; Hatoum, Nabil S.

doi:10.1016/0306-3623(83)90004-6

Cited by 64 publications

(53 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As for the other constituents in marijuana, little is known about their pharmacological and toxicological properties. CBC is not pharmacologically active in monkeys (Edery et al, 1971), lacks anticonvulsant effects (Karler and Turkanis., 1979), but was reported to produce CNS depression and slight analgesia in rodents (Davis and Hatoum, 1983). CBG does not stimulate adenylyl cyclase (Howlett, 1987), but does appear to have some weak analgesic properties (McPartland and Russo, 2001).…”

Section: Plant-derived Cannabinoidsmentioning

confidence: 99%

The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids

McAllister

Soroceanu

Desprez

2015

J Neuroimmune Pharmacol

101

View full text Add to dashboard Cite

As a therapeutic agent, most people are familiar with the palliative effects of the primary psychoactive constituent of Cannabis sativa (CS), Δ9-tetrahydrocannabinol (THC), a molecule active at both the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor subtypes. Through the activation primarily of CB1 receptors in the central nervous system, THC can reduce nausea, emesis and pain in cancer patients undergoing chemotherapy. During the last decade, however, several studies have now shown that CB1 and CB2 receptor agonists can act as direct antitumor agents in a variety of aggressive cancers. In addition to THC, there are many other cannabinoids found in CS, and a majority produces little to no psychoactivity due to the inability to activate cannabinoid receptors. For example, the second most abundant cannabinoid in CS is the non-psychoactive cannabidiol (CBD). Using animal models, CBD has been shown to inhibit the progression of many types of cancer including glioblastoma (GBM), breast, lung, prostate and colon cancer. This review will center on mechanisms by which CBD, and other plant-derived cannabinoids inefficient at activating cannabinoid receptors, inhibit tumor cell viability, invasion, metastasis, angiogenesis, and the stem-like potential of cancer stem cells. We will also discuss the ability of non-psychoactive cannabinoids to induce autophagy and apoptotic-mediated cancer cell death, and enhance the activity of first-line agents commonly used in cancer treatment.

show abstract

Section: Plant-derived Cannabinoidsmentioning

confidence: 99%

The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids

McAllister

Soroceanu

Desprez

2015

J Neuroimmune Pharmacol

101

View full text Add to dashboard Cite

show abstract

“…CBC was shown to have analgesic properties and potentiated the analgesic effects of THC in the mouse tail-flick assay (Davis et al , 1983). It also was found to prolong hexabarbital-induced hypnosis (Hatoum et al , 1981).…”

Section: Introductionmentioning

confidence: 99%

Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ9-tetrahydrocannabinol☆

DeLong

Wolf

Poklis

et al. 2010

Drug and Alcohol Dependence

View full text Add to dashboard Cite

In contrast to the numerous reports on the pharmacological effects of Δ 9 -tetrahydrocannabinol (THC), the pharmacological activity of another substituent of Cannabis sativa, cannabichromene (CBC) remains comparatively unknown. In the present study, we investigated whether CBC elicits cannabinoid activity in the tetrad assay, which consists of the following four endpoints: hypomotility, antinociception, catalepsy, and hypothermia. Because cannabinoids are well documented to possess anti-inflammatory properties, we examined CBC, THC, and combination of both phytocannabinoids in the lipopolysaccharide (LPS) paw edema assay. CBC elicited activity in the tetrad that was not blocked by the CB 1 receptor antagonist, rimonabant. Moreover, a behaviorally inactive dose of THC augmented the effects of CBC in the tetrad that was associated with an increase in THC brain concentrations. Both CBC and THC elicited dose-dependent anti-inflammatory effects in the LPSinduced paw edema model. The CB 2 receptor, SR144528 blocked the anti-edematous actions of THC, but not those produced by CBC. Isobolographic analysis revealed that the anti-edematous effects of these cannabinoids in combination were additive. Although CBC produced pharmacological effects, unlike THC, its underlying mechanism of action did not involve CB 1 or CB 2 receptors. In addition, there was evidence of a possible pharmacokinetic component in which CBC dose-dependently increased THC brain levels following an i.v. injection of 0.3 mg/kg THC. In conclusion, CBC produced a subset of behavioral activity in the tetrad assay and reduced LPS- To whom correspondence should be addressed: Aron H. Lichtman. Tel: (804) 828-8480; Fax (804) 828-2117; alichtma@vcu.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.Contributors G.T. DeLong conducted the bulk of the studies, analysis of data, and writing of the manuscript. C.E. Wolf contributed to the laboratory procedures for analytical studies. A. Poklis contributed to the design of the analytical studies. A.H. Lichtman oversaw the study, along with contributing to the writing of the manuscript. Conflict of InterestNone of the authors report a conflict of interest that could have influenced, or be perceived to influence, this work. NIH Public Access NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript induced paw edema through a noncannabinoid receptor mechanism of action. These effects were augmented when CBC and THC were co-administered.

show abstract

“…Beraz, CBGa bezala periferikoki aktiboagoa da eta, horregatik, deskribatu zaizkion propietate gehienak sistema immunologikoarekin erlazionatuta daude. Bestetik, 80ko hamarkadatik, animalia-ereduetan propietate analgesikoak ere deskribatu zaizkio [47]. Efektu hori oraindik ez da karakterizatu, baina baliteke TRP erretenen eta CB hartzaileen bidezko efektua izatea [48].…”

Section: Beste Kannabinoide Batzuk: Kannabikromenoa Kannabinoide Ahaunclassified

Kannabinoide berriak: segurtasun eta eraginkortasun terapeutikoaren bila

Aostri

Pineda

Mendiguren

2017

EKAIA

View full text Add to dashboard Cite

Laburpena:Cannabis sativa landarean kannabidiola, kannabigerola edo Δ 9 -tetrahidrokannabibarina bezalako kannabinoide ez-psikoaktiboak aurki daitezke. Oro har, kannabinoide horiek kannabinoideen hartzaileekiko (CB) afinitate txikia dutenez, ez daukate kannabinoide klasikoek (bereziki Δ 9 -THCak) duten aktibitate psikoaktiboa. Gizakietan eta animalietan kannabinoide ez-psikoaktiboekin egindako lehenengo ikerketek horien propietate terapeutikoak frogatu dituzte. Efektu horiek azaltzeko itu eta mekanismo desberdinak proposatu dira, besteak beste, hartzaile serotonergikoen aktibazioa edota entzima desberdinen modulazioa.Hitz gakoak: kannabidiola, kannabigerola, Δ 9 -tetrahidrokannabibarina, kannabinoide, 5-HT 1A hartzailea. Abstract:Cannabis sativa plant contains non-psychoactive phytocannabinoids including cannabidiol, cannabigerol or Δ 9 -tetrahydrocannabivarin. Unlike classical cannabinoids (i.e Δ 9 -THC) most of these compounds bind with low affinity to cannabinoid receptors (CB), which seems to be the reason for their lack of psychoactive effect. Preliminary studies performed in humans and animals demonstrated that these cannabinoids have therapeutic properties. Different targets and mechanisms have been proposed to explain their effects such as activation of serotonergic receptors or modulation of different enzymes.

show abstract

Neurobehavioral actions of cannabichromene and interactions with Δ9-tetrahydrocannabinol

Cited by 64 publications

References 20 publications

The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids

The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids

Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ9-tetrahydrocannabinol☆

Kannabinoide berriak: segurtasun eta eraginkortasun terapeutikoaren bila

Contact Info

Product

Resources

About